SAB Biotherapeutics Presents Overview of DiversitAb™ Platform and Data Showing Benefits of Fully-Human Polyclonal Antibodies Derived from Cows vs. Human-Derived Plasma, at 2022 Plasma Product Biotechnology Conference
SABs Chief Operating Officer Christoph Bausch, Ph.D., led two presentations at the conference on Tuesday, Nov. 1.
- SABs Chief Operating Officer Christoph Bausch, Ph.D., led two presentations at the conference on Tuesday, Nov. 1.
- Tc Bovine, SABs genetically engineered cows, mount the same immune response as humans, only with a much higher concentration of targeted neutralizing antibodies.
- Data from the in vitro neutralizing capacity of SAB-185 was tested against 10 variant SARS-CoV-2 strains, including several Omicron variants.
- Our versatile DiversitAb platform is applicable to a wide range of serious unmet needs in human diseases.